Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer

Brian P. Neuman, John B. Eifler, Mark Castanares, Wasim H. Chowdhury, Ying Chen, Ronnie Mease, Rong Ma, Amarnath Mukherjee, Shawn Lupold, Martin Gilbert Pomper, Ronald Rodriguez

Research output: Contribution to journalArticle

Abstract

Purpose: The prostate-specific membrane antigen (PSMA) is a surface glycoprotein overexpressed on malignant prostate cells, as well as in the neovasculature of many tumors. Recent efforts to target PSMA for imaging prostate cancer rely on suitably functionalized low-molecular-weight agents. YC-27 is a low-molecular-weight, urea-based agent that enables nearinfrared (NIR) imaging of PSMA in vivo. Experimental Design: We have developed and validated a laparoscopic imaging system (including an optimized light source, LumiNIR) that is capable of imaging small tumor burdens with minimal background fluorescence in real-time laparoscopic extirpative surgery of small prostate tumor xenografts in murine and porcine models. Results: In a mouse model, we demonstrate the feasibility of using real-time NIR laparoscopic imaging to detect and surgically remove PSMA-positive xenografts. We then validate the use of our laparoscopic real-time NIR imaging system in a large animal model. Our novel light source, which is optimized for YC-27, is capable of detecting as little as 12.4 pg/mL of the compound (2.48-pg YC-27 in 200-mL agarose). Finally, in a mouse xenograft model, we demonstrate that the use of real-time NIR imaging can reduce positive surgical margins (PSM). Conclusions: These data indicate that a NIR-emitting fluorophore targeted to PSMA may allow improved surgical treatment of human prostate cancer, reduce the rate of PSMs, and alleviate the need for adjuvant radiotherapy postoperatively.

Original languageEnglish (US)
Pages (from-to)771-780
Number of pages10
JournalClinical Cancer Research
Volume21
Issue number4
DOIs
StatePublished - Feb 15 2015

Fingerprint

Optical Imaging
Prostatic Neoplasms
Coloring Agents
Light
Heterografts
Prostate
Molecular Weight
Adjuvant Radiotherapy
Membrane Glycoproteins
Tumor Burden
Laparoscopy
Sepharose
Urea
Neoplasms
Research Design
Swine
Animal Models
Fluorescence
human glutamate carboxypeptidase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. / Neuman, Brian P.; Eifler, John B.; Castanares, Mark; Chowdhury, Wasim H.; Chen, Ying; Mease, Ronnie; Ma, Rong; Mukherjee, Amarnath; Lupold, Shawn; Pomper, Martin Gilbert; Rodriguez, Ronald.

In: Clinical Cancer Research, Vol. 21, No. 4, 15.02.2015, p. 771-780.

Research output: Contribution to journalArticle

Neuman, Brian P. ; Eifler, John B. ; Castanares, Mark ; Chowdhury, Wasim H. ; Chen, Ying ; Mease, Ronnie ; Ma, Rong ; Mukherjee, Amarnath ; Lupold, Shawn ; Pomper, Martin Gilbert ; Rodriguez, Ronald. / Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 4. pp. 771-780.
@article{16eb388a0f584c7186c988d1eb381642,
title = "Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer",
abstract = "Purpose: The prostate-specific membrane antigen (PSMA) is a surface glycoprotein overexpressed on malignant prostate cells, as well as in the neovasculature of many tumors. Recent efforts to target PSMA for imaging prostate cancer rely on suitably functionalized low-molecular-weight agents. YC-27 is a low-molecular-weight, urea-based agent that enables nearinfrared (NIR) imaging of PSMA in vivo. Experimental Design: We have developed and validated a laparoscopic imaging system (including an optimized light source, LumiNIR) that is capable of imaging small tumor burdens with minimal background fluorescence in real-time laparoscopic extirpative surgery of small prostate tumor xenografts in murine and porcine models. Results: In a mouse model, we demonstrate the feasibility of using real-time NIR laparoscopic imaging to detect and surgically remove PSMA-positive xenografts. We then validate the use of our laparoscopic real-time NIR imaging system in a large animal model. Our novel light source, which is optimized for YC-27, is capable of detecting as little as 12.4 pg/mL of the compound (2.48-pg YC-27 in 200-mL agarose). Finally, in a mouse xenograft model, we demonstrate that the use of real-time NIR imaging can reduce positive surgical margins (PSM). Conclusions: These data indicate that a NIR-emitting fluorophore targeted to PSMA may allow improved surgical treatment of human prostate cancer, reduce the rate of PSMs, and alleviate the need for adjuvant radiotherapy postoperatively.",
author = "Neuman, {Brian P.} and Eifler, {John B.} and Mark Castanares and Chowdhury, {Wasim H.} and Ying Chen and Ronnie Mease and Rong Ma and Amarnath Mukherjee and Shawn Lupold and Pomper, {Martin Gilbert} and Ronald Rodriguez",
year = "2015",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-14-0891",
language = "English (US)",
volume = "21",
pages = "771--780",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer

AU - Neuman, Brian P.

AU - Eifler, John B.

AU - Castanares, Mark

AU - Chowdhury, Wasim H.

AU - Chen, Ying

AU - Mease, Ronnie

AU - Ma, Rong

AU - Mukherjee, Amarnath

AU - Lupold, Shawn

AU - Pomper, Martin Gilbert

AU - Rodriguez, Ronald

PY - 2015/2/15

Y1 - 2015/2/15

N2 - Purpose: The prostate-specific membrane antigen (PSMA) is a surface glycoprotein overexpressed on malignant prostate cells, as well as in the neovasculature of many tumors. Recent efforts to target PSMA for imaging prostate cancer rely on suitably functionalized low-molecular-weight agents. YC-27 is a low-molecular-weight, urea-based agent that enables nearinfrared (NIR) imaging of PSMA in vivo. Experimental Design: We have developed and validated a laparoscopic imaging system (including an optimized light source, LumiNIR) that is capable of imaging small tumor burdens with minimal background fluorescence in real-time laparoscopic extirpative surgery of small prostate tumor xenografts in murine and porcine models. Results: In a mouse model, we demonstrate the feasibility of using real-time NIR laparoscopic imaging to detect and surgically remove PSMA-positive xenografts. We then validate the use of our laparoscopic real-time NIR imaging system in a large animal model. Our novel light source, which is optimized for YC-27, is capable of detecting as little as 12.4 pg/mL of the compound (2.48-pg YC-27 in 200-mL agarose). Finally, in a mouse xenograft model, we demonstrate that the use of real-time NIR imaging can reduce positive surgical margins (PSM). Conclusions: These data indicate that a NIR-emitting fluorophore targeted to PSMA may allow improved surgical treatment of human prostate cancer, reduce the rate of PSMs, and alleviate the need for adjuvant radiotherapy postoperatively.

AB - Purpose: The prostate-specific membrane antigen (PSMA) is a surface glycoprotein overexpressed on malignant prostate cells, as well as in the neovasculature of many tumors. Recent efforts to target PSMA for imaging prostate cancer rely on suitably functionalized low-molecular-weight agents. YC-27 is a low-molecular-weight, urea-based agent that enables nearinfrared (NIR) imaging of PSMA in vivo. Experimental Design: We have developed and validated a laparoscopic imaging system (including an optimized light source, LumiNIR) that is capable of imaging small tumor burdens with minimal background fluorescence in real-time laparoscopic extirpative surgery of small prostate tumor xenografts in murine and porcine models. Results: In a mouse model, we demonstrate the feasibility of using real-time NIR laparoscopic imaging to detect and surgically remove PSMA-positive xenografts. We then validate the use of our laparoscopic real-time NIR imaging system in a large animal model. Our novel light source, which is optimized for YC-27, is capable of detecting as little as 12.4 pg/mL of the compound (2.48-pg YC-27 in 200-mL agarose). Finally, in a mouse xenograft model, we demonstrate that the use of real-time NIR imaging can reduce positive surgical margins (PSM). Conclusions: These data indicate that a NIR-emitting fluorophore targeted to PSMA may allow improved surgical treatment of human prostate cancer, reduce the rate of PSMs, and alleviate the need for adjuvant radiotherapy postoperatively.

UR - http://www.scopus.com/inward/record.url?scp=84923164097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923164097&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-0891

DO - 10.1158/1078-0432.CCR-14-0891

M3 - Article

C2 - 25501577

AN - SCOPUS:84923164097

VL - 21

SP - 771

EP - 780

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -